Combined caveolin‑1 and epidermal growth factor receptor expression as a prognostic marker for breast cancer

Liang,Ya‑Nan; Liu,Yu; Wang,Letian; Yao,Guodong; Li,Xiaobo; Meng,Xiangning; Wang,Fan; Li,Ming; Tong,Dandan; Geng,Jingshu

doi:10.3892/ol.2018.8533

Combined caveolin‑1 and epidermal growth factor receptor expression as a prognostic marker for breast cancer

Authors:
- Ya‑Nan Liang
- Yu Liu
- Letian Wang
- Guodong Yao
- Xiaobo Li
- Xiangning Meng
- Fan Wang
- Ming Li
- Dandan Tong
- Jingshu Geng
View Affiliations

Affiliations: College of Pharmacy, Harbin Medical University, Harbin, Heilongjiang 150081, P.R. China, Department of Pathology, Harbin Medical University, Harbin, Heilongjiang 150081, P.R. China, College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, Heilongjiang 150081, P.R. China, Department of Pathology, The Third Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150081, P.R. China, Department of Medical Genetics, Harbin Medical University, Harbin, Heilongjiang 150081, P.R. China, School of Public Health, Harbin Medical University, Harbin, Heilongjiang 150081, P.R. China
Published online on: April 18, 2018 https://doi.org/10.3892/ol.2018.8533
Pages: 9271-9282

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Previous studies have indicated that caveolin‑1 (Cav‑1) is able to bind the signal transduction factor epidermal growth factor receptor (EGFR) to regulate its tyrosine kinase activity. The aim of the present study was to evaluate the clinical significance of Cav‑1 gene expression in association with the expression of EGFR in patients with breast cancer. Primary breast cancer samples from 306 patients were analyzed for Cav‑1 and EGFR expression using immunohistochemistry, and clinical significance was assessed using multivariate Cox regression analysis, Kaplan‑Meier estimator curves and the log‑rank test. Stromal Cav‑1 was downregulated in 38.56% (118/306) of tumor tissues, whereas cytoplasmic EGFR and Cav‑1 were overexpressed in 53.92% (165/306) and 44.12% (135/306) of breast cancer tissues, respectively. EGFR expression was positively associated with cytoplasmic Cav‑1 and not associated with stromal Cav‑1 expression in breast cancer samples; however, low expression of stromal Cav‑1 was negatively associated with cytoplasmic Cav‑1 expression in total tumor tissues, and analogous results were identified in the chemotherapy group. Multivariate Cox's proportional hazards model analysis revealed that, for patients in the estrogen receptor (ER)(+) group, the expression of stromal Cav‑1 alone was a significant prognostic marker of breast cancer. However, in the chemotherapy, human epidermal growth factor receptor 2 (HER‑2)(‑), HER‑2(+) and ER(‑) groups, the use of combined markers was more effective prognostic marker. Stromal Cav‑1 has a tumor suppressor function, and the combined marker stromal Cav‑1/EGFR expression was identified as an improved prognostic marker in the diagnosis of breast cancer. Parenchymal expression of Cav‑1 is able to promote EGFR signaling in breast cancer, potentially being required for EGFR‑mediated initiation of mitosis.

View Figures

View References

1	Liedtke C, Kersting C, Bürger H, Kiesel L and Wülfing P: Caveolin-1 expression in benign and malignant lesions of the breast. World J Surg Oncol. 5:1102007. View Article : Google Scholar : PubMed/NCBI
2	Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005. View Article : Google Scholar : PubMed/NCBI
3	Engelman JA, Zhang XL, Galbiati F and Lisanti MP: Chromosomal localization, genomic organization, and developmental expression of the murine caveolin gene family (Cav-1, −2 and −3). Cav-1 and Cav-2 genes map to a known tumor suppressor locus (6-A2/7q31). FEBS Lett. 429:330–336. 1998. View Article : Google Scholar : PubMed/NCBI
4	Engelman JA, Zhang XL and Lisanti MP: Genes encoding human caveolin-1 and −2 are co-localized to the D7S522 locus (7q31.1), a known fragile site (FRA7G) that is frequently deleted in human cancers. FEBS Lett. 436:403–410. 1998. View Article : Google Scholar : PubMed/NCBI
5	Okamoto T, Schlegel A, Scherer PE and Lisanti MP: Caveolins, a family of scaffolding proteins for organizing ‘preassembled signaling complexes’ at the plasma membrane. J Biol Chem. 273:5419–5422. 1998. View Article : Google Scholar : PubMed/NCBI
6	Hnasko R and Lisanti MP: The biology of caveolae: Lessons from caveolin knockout mice and implications for human disease. Mol Interv. 3:445–464. 2003. View Article : Google Scholar : PubMed/NCBI
7	Engelman JA, Zhang X, Galbiati F, Volonte D, Sotgia F, Pestell RG, Minetti C, Scherer PE, Okamoto T and Lisanti MP: Molecular genetics of the caveolin gene family: Implications for human cancers, diabetes, Alzheimer disease, and muscular dystrophy. Am J Hum Genet. 63:1578–1587. 1998. View Article : Google Scholar : PubMed/NCBI
8	Zhang W, Razani B, Altschuler Y, Bouzahzah B, Mostov KE, Pestell RG and Lisanti MP: Caveolin-1 inhibits epidermal growth factor-stimulated lamellipod extension and cell migration in metastatic mammary adenocarcinoma cells (MTLn3). Transformation suppressor effects of adenovirus-mediated gene delivery of caveolin-1. J Biol Chem. 275:20717–20725. 2000. View Article : Google Scholar : PubMed/NCBI
9	Smart EJ, Graf GA, McNiven MA, Sessa WC, Engelman JA, Scherer PE, Okamoto T and Lisanti MP: Caveolins, liquid-ordered domains, and signal transduction. Mol Cell Biol. 19:7289–7304. 1999. View Article : Google Scholar : PubMed/NCBI
10	Koleske AJ, Baltimore D and Lisanti MP: Reduction of caveolin and caveolae in oncogenically transformed cells. Proc Natl Acad Sci USA. 92:1381–1385. 1995. View Article : Google Scholar : PubMed/NCBI
11	Quest AF, Gutierrez-Pajares JL and Torres VA: Caveolin-1: An ambiguous partner in cell signalling and cancer. J Cell Mol Med. 12:1130–1150. 2008. View Article : Google Scholar : PubMed/NCBI
12	Sloan EK, Ciocca DR, Pouliot N, Natoli A, Restall C, Henderson MA, Fanelli MA, Cuello-Carrión FD, Gago FE and Anderson RL: Stromal cell expression of caveolin-1 predicts outcome in breast cancer. Am J Pathol. 174:2035–2043. 2009. View Article : Google Scholar : PubMed/NCBI
13	El-Gendi SM, Mostafa MF and El-Gendi AM: Stromal caveolin-1 expression in breast carcinoma. Correlation with early tumor recurrence and clinical outcome. Pathol Oncol Res. 18:459–469. 2012. View Article : Google Scholar : PubMed/NCBI
14	Witkiewicz AK, Dasgupta A, Sotgia F, Mercier I, Pestell RG, Sabel M, Kleer CG, Brody JR and Lisanti MP: An absence of stromal caveolin-1 expression predicts early tumor recurrence and poor clinical outcome in human breast cancers. Am J Pathol. 174:2023–2034. 2009. View Article : Google Scholar : PubMed/NCBI
15	Couet J, Sargiacomo M and Lisanti MP: Interaction of a receptor tyrosine kinase, EGF-R, with caveolins. Caveolin binding negatively regulates tyrosine and serine/threonine kinase activities. J Biol Chem. 272:30429–30438. 1997. View Article : Google Scholar : PubMed/NCBI
16	Lajoie P, Partridge EA, Guay G, Goetz JG, Pawling J, Lagana A, Joshi B, Dennis JW and Nabi IR: Plasma membrane domain organization regulates EGFR signaling in tumor cells. J Cell Biol. 179:341–356. 2007. View Article : Google Scholar : PubMed/NCBI
17	Park WY, Park JS, Cho KA, Kim DI, Ko YG, Seo JS and Park SC: Up-regulation of caveolin attenuates epidermal growth factor signaling in senescent cells. J Biol Chem. 275:20847–20852. 2000. View Article : Google Scholar : PubMed/NCBI
18	Savage K, Lambros MB, Robertson D, Jones RL, Jones C, Mackay A, James M, Hornick JL, Pereira EM, Milanezi F, et al: Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: A morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis. Clin Cancer Res. 13:90–101. 2007. View Article : Google Scholar : PubMed/NCBI
19	Agelaki S, Spiliotaki M, Markomanolaki H, Kallergi G, Mavroudis D, Georgoulias V and Stournaras C: Caveolin-1 regulates EGFR signaling in MCF-7 breast cancer cells and enhances gefitinib-induced tumor cell inhibition. Cancer Biol Ther. 8:1470–1477. 2009. View Article : Google Scholar : PubMed/NCBI
20	Ferrero JM, Ramaioli A, Largillier R, Formento JL, Francoual M, Ettore F, Namer M and Milano G: Epidermal growth factor receptor expression in 780 breast cancer patients: A reappraisal of the prognostic value based on an eight-year median follow-up. Ann Oncol. 12:841–846. 2001. View Article : Google Scholar : PubMed/NCBI
21	Jorge SE, Kobayashi SS and Costa DB: Epidermal growth factor receptor (EGFR) mutations in lung cancer: Preclinical and clinical data. Braz J Med Biol Res. 47:929–939. 2014. View Article : Google Scholar : PubMed/NCBI
22	Sordella R, Bell DW, Haber DA and Settleman J: Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science. 305:1163–1167. 2004. View Article : Google Scholar : PubMed/NCBI
23	Salomon DS, Brandt R, Ciardiello F and Normanno N: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 19:183–232. 1995. View Article : Google Scholar : PubMed/NCBI
24	Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
25	Lee JC, Vivanco I, Beroukhim R, Huang JH, Feng WL, DeBiasi RM, Yoshimoto K, King JC, Nghiemphu P, Yuza Y, et al: Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med. 3:e4852006. View Article : Google Scholar : PubMed/NCBI
26	Lafky JM, Wilken JA, Baron AT and Maihle NJ: Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer. Biochim Biophys Acta. 1785:232–265. 2008.PubMed/NCBI
27	Koenders PG, Beex LV, Kienhuis CB, Kloppenborg PW and Benraad TJ: Epidermal growth factor receptor and prognosis in human breast cancer: A prospective study. Breast Cancer Res Treat. 25:21–27. 1993. View Article : Google Scholar : PubMed/NCBI
28	Mineo C, Gill GN and Anderson RG: Regulated migration of epidermal growth factor receptor from caveolae. J Biol Chem. 274:30636–30643. 1999. View Article : Google Scholar : PubMed/NCBI
29	Hoop CL, Sivanandam VN, Kodali R, Srnec MN and van der Wel PC: Structural characterization of the caveolin scaffolding domain in association with cholesterol-rich membranes. Biochemistry. 51:90–99. 2012. View Article : Google Scholar : PubMed/NCBI
30	Edge SB and Compton CC: The American Joint Committee on Cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010. View Article : Google Scholar : PubMed/NCBI
31	Cohen AW, Razani B, Wang XB, Combs TP, Williams TM, Scherer PE and Lisanti MP: Caveolin-1-deficient mice show insulin resistance and defective insulin receptor protein expression in adipose tissue. Am J Physiol Cell Physiol. 285:C222–C235. 2003. View Article : Google Scholar : PubMed/NCBI
32	Lee SW, Reimer CL, Oh P, Campbell DB and Schnitzer JE: Tumor cell growth inhibition by caveolin re-expression in human breast cancer cells. Oncogene. 16:1391–1397. 1998. View Article : Google Scholar : PubMed/NCBI